Education
About Us
Working with TipRanks
Follow Us
aTyr Pharma (DE:471A)
FRANKFURT:471A
471A Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.32 - €4.40
Previous CloseN/A
Volume750.00
Average Volume (3M)372.00
Market Cap
$239.66M
Enterprise Value€80.81M
Total Cash (Recent Filing)$2.34M
Total Debt (Recent Filing)$1.38M
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Mar 13, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding83,942,406
10 Day Avg. Volume25
30 Day Avg. Volume372
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1214.49
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.34
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.84
Enterprise Value/Ebitda-1.22
Forecast
1Y Price Target
€17.04Price Target Upside453.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe independent DSMB recommended the Phase 3 EFZO-FIT trial in pulmonary sarcoidosis to continue without any modifications, indicating a lack of safety concerns.
Therapeutic PotentialEfzofitimod has the potential to be a transformative treatment in a high need indication, presenting a compelling risk/reward opportunity.
Bears Say
Data UpdatesExpected updates from aTyr's programs include a significant focus on long-term data, which might delay immediate results.
---
Options Prices
Currently, No data available
---
Ownership Overview
2.67% Insiders
30.32% Mutual Funds
13.12% Other Institutional Investors
49.30% Public Companies and Individual Investors
471A FAQ
What was aTyr Pharma’s price range in the past 12 months?
aTyr Pharma lowest stock price was €1.32 and its highest was €4.40 in the past 12 months.
What is aTyr Pharma’s market cap?
aTyr Pharma’s market cap is $239.66M.
When is aTyr Pharma’s upcoming earnings report date?
aTyr Pharma’s upcoming earnings report date is Mar 13, 2025 which is tomorrow.
How were aTyr Pharma’s earnings last quarter?
aTyr Pharma released its earnings results on Nov 07, 2024. The company reported -€0.212 earnings per share for the quarter, missing the consensus estimate of -€0.203 by -€0.009.
Is aTyr Pharma overvalued?
According to Wall Street analysts aTyr Pharma’s price is currently Undervalued.
Does aTyr Pharma pay dividends?
aTyr Pharma does not currently pay dividends.
What is aTyr Pharma’s EPS estimate?
aTyr Pharma’s EPS estimate is -0.21.
How many shares outstanding does aTyr Pharma have?
aTyr Pharma has 83,942,406 shares outstanding.
What happened to aTyr Pharma’s price movement after its last earnings report?
aTyr Pharma reported an EPS of -€0.212 in its last earnings report, missing expectations of -€0.203. Following the earnings report the stock price went down -5.333%.
Which hedge fund is a major shareholder of aTyr Pharma?
Currently, no hedge funds are holding shares in DE:471A
---
aTyr Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.04 (453.18% Upside)
€17.04 (453.18% Upside)
Blogger Sentiment
Bullish
DE:471A Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.96%
12-Months-Change
Fundamentals
Return on Equity
-77.96%
Trailing 12-Months
Asset Growth
-26.75%
Trailing 12-Months
Company Description
aTyr Pharma
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
---
471A Stock 12 Month Forecast
Average Price Target
€17.04
▲(453.18% Upside)
Technical Analysis
Fate Therapeutics
―
Blueprint Medicines
―
Seres Therapeutics
―
Kiniksa Pharmaceuticals
―
Arcutis Biotherapeutics
―
Best Analysts Covering 471A
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+71.55%
reiterated a buy rating 3 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +71.55% per trade.
---